Abstract Lithium preparations have been successfully used to treat bipolar disorder (BD), and remain the best established long-term treatment for the disorder. In fact, lithium is a cornerstone of treatment to minimize the risk of recurrences and improve inter-episodic symptomatology. We reviewed the available evidence for the use of lithium in the treatment of BD, including its efficacy, limitations, and potential benefits also in consideration of the different formulations available. We also overviewed salient comparative aspects regarding the long-term alternative use of anticonvulsants, antidepressants, and antipsychotics in BD patients. The available evidence indicates that BD patients should be treated primarily with lithium, combined in some cases with antipsychotics especially in acute treatments, and sometimes, because of intolerance or inefficacy of lithium, with anticonvulsants. The use of adjunctive antidepressants should be limited to episodes of breakthrough depression. Lithium should be offered to the majority of BD patients as initial treatment especially when suicide ideation or behavior is present with adequate information about its long-term benefits and its potential side effects. Many patients can tolerate lithium without concomitant use of antidepressants, which may worsen the course of the illness or antipsychotics, which may cause severe long-term side effects.
Introduction
Bipolar disorder (BD) is characterized by episodic recurrences of mania or hypomania and depression with or without mixed or psychotic features at rates that vary markedly among individuals. BD is one of the most prevalent and severe mental disorders, with an estimated, cautious lifetime prevalence of 2.4% [1] . DSM-5 categorize BD according to its longitudinal course. Diagnosis of All authors contributed equally to this paper.
& Gabriele Sani gabriele.sani@uniroma1.it BP type I (BD-I) requires at least one manic episode. Major depressive episodes are also typical but not always present [2] . BD type II (BD-II) requires the presence of at least one hypomanic episode and one major depressive episode. In addition, BD is commonly characterized by the presence of inter-episodic symptoms, such as emotionality, impulsivity, and exaggerated mood reactivity and instability. BD-II presents with a higher frequency of episodes compared to BD-I, especially depressive. The aggregate lifetime prevalence is 0.6% for BD-I, 0.4% for BD-II, 1.4% for subthreshold bipolar disorder, and 2.4% for the bipolar disorder spectrum [1] . Both types of BDs may be associated with suicidal ideation or behavior.
Even during a long-term treatment, only about 60% of patients achieve substantial improvement, and the 5-year risk of relapse into mania or depression has been reported to be 73%, despite continued maintenance treatment [3] . In a study of BD-I patients followed up for 12.8 years, symptoms were present 47.3% of the time, depressive for 31.9%, manic/hypomanic symptoms for 8.9%, and cycling/ mixed symptoms for 5.9% [4] . In addition, treated BD-I patients spend about 50% of their time in an ill state which is depressive in 75% of that time [5] .
Medical intervention in BD patients generally initiates with acute treatment of depressive or manic episodes followed by long-term therapy in most cases. The main goal of long-term treatment is prevention of recurrences and mitigation of subthreshold symptoms, in order to improve levels of relational, social, and occupational functioning. Treatment may be complicated by the common presence of other mental disorders and medical comorbidities, more prevalent in BD patients than in the general population, including cardiovascular diseases, type 2 diabetes, and obesity [6] .
Lithium is the prototypical mood-stabilizing agent in the long-term treatment of bipolar manic-depressive illness [7] and it is also the most extensively studied treatment for BD, even if a variety of anticonvulsants and modern antipsychotics have emerged [8] . Promotion of alternatives to lithium has also led, in some cases, to unjustified implications that lithium has inferior efficacy to other alternatives, especially in some diagnostic subgroups (rapid cycling course or with mixed states) [8] . Lithium is considered a first-line treatment in the major guidelines for therapy of BD, and still plays a prominent role in acute and long-term management of the illness [9, 10] .
Since their introduction over 65 years ago [11] , lithium preparations have been successfully used to treat BD patients, and generally remain the best established longterm treatment for the disorder [12, 13] . Lithium is a mainstay to minimize the risk of recurrences and improve inter-episodic symptomatology. In addition, its common side effects are less dangerous than the neurologic and metabolic side effects associated with the long-term use of antipsychotics and does not increase the risk of switches into manic episodes and cycle acceleration as happens often with the use of antidepressants [6, 13] . There are some findings showing that treatment should be started as early as possible. In fact, response rates for mania and for long-term treatments decrease in individuals with [5 previous episodes [14] . As a consequence, it is recommended that long-term lithium treatment should be started after two manic episodes or after just one but severe or psychotic [15] .
Despite all the evidence gathered in over more than 60 years of research and clinical observation and recommendations in clinical guidelines [16] , the use of lithium has decreased during the years [17] and it is still severely under prescribed even in patients for whom it should be the treatment of first choice, such as suicidal patients with BD [18] .
The objective of the present report is to give an overview on evidence-based perspective for the use of lithium in long-term treatment of BD, including its efficacy, limitations, and side effects, also in consideration of the different formulations available. In addition, we overview salient comparative aspects regarding the long-term alternative use of anticonvulsants, antidepressants, and antipsychotics in BD patients.
Methods
We performed an extensive review of the major publications about lithium. Furthermore, a PubMed search was made to examine articles using the following keywords: 'lithium' OR 'antipsychotics' OR 'antidepressants' OR 'anticonvulsants' AND 'long-term treatment' OR 'lifetime treatment'. Additionally, references in the paper were examined to obtain further relevant publications. Given the objective of this critical overview, the papers were not systematically reviewed, but important relevant references were used to supplement the discussion. No time or language restrictions were applied.
Lithium: Pharmacodynamic Properties
A wide variety of pathways and mechanisms have been invoked in the mechanism of action of lithium. At the cellular level, lithium has effects on multiple transmitter receptors, such as serotonin and adrenoceptors, on second messenger systems like the phosphoinositide cycle, interference with glycogen synthase kinase-3beta (GSK-3b) function, and the calcium-calmodulin systems; hence, it modulates neurotransmission, thus facilitating cellular viability by promoting anti-oxidant defenses, decreasing apoptosis, and possibly increasing neuroprotective proteins [19] . Moreover, it may have some effects on the expression of a multitude of genes [20] . Determining which mechanisms are important from a therapeutic standpoint has been challenging, and further research is needed in this regard.
Lithium in a Lifetime Perspective

Use in the Acute Phase
Many randomized clinical trials and meta-analyses have shown the superior efficacy of standard doses of lithium (0.6-0.8 mEq/L) versus placebo in the treatment of manic or mixed episodes [21] [22] [23] . Moreover, guidelines developed from existing evidence from clinical trials commonly consider that lithium has benefits in the treatment of recurrences of mania (or hypomania), mixed states, or bipolar depression, especially with dysphoric-agitated or mixed features [8, 24] . For partial responders or non-responders to monotherapy for a manic episode, adjunctive valproate or a second-generation antipsychotic is commonly recommended [9] . The addition of an antipsychotic is often needed for rapid control of the manic state, especially in patients with severe psychomotor agitation, psychotic symptoms, poor collaboration, or low adherence to therapy [25] . The addition of sodium valproate at a dose of 20 mg/kg appears to rapidly potentiate the antimanic effects of lithium [26] .
Even if the efficacy of lithium in acute depressive episodes is controversial, it is still recognized in guidelines and in clinical practice as a therapeutic option in bipolar depression as both monotherapy and in combination with antidepressants [15, [27] [28] [29] . However, these are indications from studies that should not be considered definitive because of their short duration and uncertainty about the diagnostic accuracy of depressive episodes treated. A double-blind, placebo-controlled trial demonstrated that quetiapine is more effective than placebo in treatment of acute depressive episodes of BD, while neither paroxetine nor lithium have shown greater efficacy than placebo [30, 31] . The concomitant use of antidepressants is suggested for short periods if patients have responded previously to such agents [32] . Lithium, usually with a second mood stabilizer, is also used in BD patients for the treatment of comorbid symptomatology such as anxiety [33] and substance use or dependence [34, 35] .
Long-Term Use
The lifelong management of patients with bipolar disorder is challenging because of the dynamic, chronic, and fluctuating symptoms of the disease. Lithium may be recommended as a first-line treatment for the maintenance phase, also supported by good-quality evidence for efficacy [15, 36] . In addition, better response to lithium is attained in the sequence course characterized by a depressive episode following mania and a free interval (MDI) compared to a sequence with mania or hypomania following a depression (DMI) [37] .
In general, the performance of long-term treatment with lithium has compared favorably with other options. In an analysis of 15 randomized clinical trials involving over 5000 participants, lithium as well as quetiapine, long-acting injection of risperidone, aripiprazole, and olanzapine were effective in prevention of recurrence of manic episodes [38] , while lamotrigine, quetiapine, and lithium were effective for the prevention of depressive relapses. Of note, antipsychotics, especially in long-term treatments, have important limitations such as body-weight gain or hematologic alterations [39] . The relevance of a long-term treatment of BD patients is also supported by the elevated rates of other medical comorbidities which are often associated with higher prevalence of mortality and a worse course of the illness [40] . These comorbidities, such as metabolic abnormalities and cardiovascular disorders, may be worsened with the concomitant administration of antipsychotics. Polarity index (PI) indicates the relative antimanic versus antidepressive efficacy: a value [1.0 indicates greater antimanic efficacy as prophylaxis, while a value \1.0 indicated that the drug has more relative antidepressive efficacy [38] . The PI was also analyzed for different maintenance treatments of BD [38, 41] . This finding further suggests that lithium may have a well-balanced efficacy in BD patients, with slightly stronger antimanic than antidepressant long-term preventive efficacy.
The benefits of lithium have been demonstrated in both monotherapy and in combination with other drugs by several meta-analyses. In these studies, lithium provided better prophylaxis for mania, hypomania, and mixed episodes than for depression [42] ; significantly reduced the risk of all relapses and manic relapses versus placebo (data from 1970 to 2006) [43] ; and confirmed its efficacy in the maintenance phase of bipolar disorder [44] .
Lithium discontinuation in BD after successful maintenance monotherapy is not recommended [45] . In one study, patients continuing on lithium prophylaxis experienced the risk of recurrence equivalent to one-third of that suffered by discontinued patients during the first year of treatment (relative risk = 0.15 vs. 0.45), and significant survival differences persisted throughout follow-up [46] . If discontinuation is necessary, it is highly recommended that should be gradual (more than a month) rather than rapid [47] . Median survival time to illness recurrence for patients continued on lithium prophylaxis was 7.33 years [95% confidence interval (CI) 5.67-9.67]; and for patients who discontinued lithium, it was 1.33 years (95% CI 0.33-2.33).
Prevention of Suicidal Behavior
A number of studies have reported that the risk of suicidal behavior, including life-threatening attempts and suicides, is significantly reduced during long-term treatment of BD patients with lithium [48, 49] with a more significant effect compared to other mood stabilizing agents [50] . A systematic review and meta-analysis of data from 48 randomized controlled trials (RCTs) involving 6674 participants reported that lithium was more effective than placebo in reducing the number of suicides [odds ratio (OR) = 0.13, 95% CI 0.03-0.66] and deaths from any cause (OR = 0.38, 95% CI 0.15-0.95) [51] . Moreover, in unipolar depression, lithium, compared to placebo, was also associated with a reduced risk of suicide (OR = 0.36, 95% CI 0.13-0.98) and number of total deaths (OR = 0.13, 95% CI 0.02-0.76), confirming the results of another study [52] . The favorable effects of lithium on prevention of suicide was also recently assessed through analysis of 14,396 electronic health records of individuals with a diagnosis of BD in the UK [53] . The authors concluded that the data support and confirm the hypothesis that lithium use reduces impulsive and aggressive traits in addition to stabilizing mood [54] and that it may have an effect on the reduction of suicide risk independent from its effect on the prevention of manic and depressive episodes [55] . However, it is also possible that the effect of lithium on suicidal prevention is related to a decrease in manic and depressive episodes [56] . It has been estimated also that the number needed to treat (NNT) is about 23 (95% CI 21-25) in order to avoid one life-threatening or fatal suicidal act [57] ; this relatively large NNT may reflect the low prevalence of suicidal acts. Lithium discontinuation, in addition to the increase of manic-depressive recurrences, may also lead to a rebound of suicidal behavior in BD patients [58] . In fact, the rates of suicidal acts have been reported to increase by about 20-fold in the first 12 months after discontinuing maintenance treatment with lithium. After one year, however, the rate drops to the pre-lithium level [59] . Moreover, the risk was two-fold higher in those undergoing abrupt or rapid versus gradual (over C2 weeks) discontinuation. Consequently, a recent review by the European Psychiatric Association recommended use of long-term treatment with lithium in order to reduce the risk of suicidal behavior in BD patients [60] .
Neuroprotection
Recent evidence has pointed to the existence of a neuroprotective effect for lithium. Gross brain structure is relatively preserved during the early phases of BD, but alterations have been observed in chronic and more recurrent forms of the illness [61] . Progressive gray matter reduction has been associated with chronicity in people with BD-I [62] .
The overall effect of lithium appears to be an increase or ''normalization'' of gray matter volume, particularly in the hippocampus, the amygdala, the anterior and the subgenual cingulate cortices [63] . This effect is not shared with other mood stabilizers. However, the short-term neurotrophic effect of lithium has been questioned [64] . In fact, only patients with long-term exposure to lithium have hippocampal volumes similar to those of healthy controls [65] . An epidemiological confirmation of this finding is provided by large case-registry studies that found a significantly lower risk of dementia in BD patients continuously treated with lithium compared to those on other mood stabilizers or without treatment [66] . In a cross-sectional study, Nunes et al [67] found that older BD patients (mean age 67.4 years) on chronic lithium treatment (average 71.2 months) had a significantly lower incidence of Alzheimer's disease (AD) (5%) than those with no or minimal lifetime lithium exposure (33%) [67] . In that study, the incidence of AD in the group treated with lithium was comparable to that in the general population, suggesting that chronic lithium treatment can be protective against the development of dementia (particularly AD) in patients with a long history of BD.
Since the protein GSK-3b, a main target of lithium, is believed to play a key role in the pathogenesis of many neuropsychiatric disorders, it has been hypothesized that the potential neuroprotective effect of lithium may be mainly associated with its inhibition of GSK-3b. This enzyme is active in a number of central intracellular signaling pathways, including cellular proliferation, migration, glucose regulation, and apoptosis [68] . Chronic lithium administration provides further in vivo evidence of a dual role for GSK-3b-related inhibition of the apoptosis.
A large body of literature has described the neuroprotective effects of lithium, whereby lithium counteracted the effects of multiple stimuli that induce neuronal apoptosis through the intrinsic pathway [69] . Whether this effect is related to complete or partial neurocognitive improvement in patients with BD is still debated, and further research aiming at studying this topic with specific tools is needed [70] .
Use in Special Populations
Use in Pregnancy and Breast-Feeding
Most recent studies have consistently denied the myth of greater mood stability in women with bipolar disorder during pregnancy. In the past, it was believed that mood stability was due to a combination of positive sentiments associated with pregnancy and higher levels of sex hormones. In reality, in both major depressive disorder and BD, the risk of relapse during pregnancy is elevated. This is especially true in BD patients during the first trimester [71, 72] , and for depressive episodes in both BD-I and -II. In the case of interruption of therapy with mood stabilizers and with lithium in particular, just prior to pregnancy or in the first trimester, the risk of relapse during pregnancy is two-to three-fold higher than those who continue therapy and is even greater in the case of rapid discontinuation. In addition, a recent review reported that the risks for the fetus are present not only with lithium, but also with other mood stabilizers [73] . In general, it can be affirmed that, if adequate monitoring is performed, lithium is sufficiently safe and minimizes the risk of relapse that can be more damaging for the fetus and mother than the therapy itself.
There are several factors to consider when evaluating the potential negative effects on the fetus or neonate if treatment with lithium is continued during pregnancy. First, it should be considered that the rates of fetal malformations in healthy women who are not on any medications varies between 2 and 4% [74] . Moreover, an untreated manic or depressive episode may be associated with negative consequences not only during pregnancy, but also in the perinatal period, in terms of increased risk for C-section, preterm labor, and reduction in circumference of the neonatal cranium [75] . Several confounding factors can increase the risk of fetal suffering or malformation that are related to the lifestyle of many women with BD, such as cigarette smoking and abuse of alcohol and other substances. Taking this into account, a causal relation between an adverse fetal event and the potential use of lithium during pregnancy is almost impossible to establish in a definitive manner. In a recent analysis, the use of lithium in pregnancy was considered to be both useful and safe [76] . Lithium is found in breast milk at a concentration that is about one-half that in plasma, and in fetal plasma is present at levels of 50 and 20% of those found in the mother, respectively [77] . In clinical practice, breast-feeding should be avoided and the use of artificial milk is recommended, or, alternatively, lithium can be suspended during breast-feeding after careful assessment of the risk/benefit ratio for the patient.
Use in Pediatric and Adolescent Patients
Lithium should not be administered to patients under the age of 12 years as no data on safety or on the efficacy are available in this age group, and the dose has yet to be established. For patients over the age of 12 years, the doses and the relative serum levels are similar to those in adult patients. In some cases, to obtain adequate plasma levels, higher doses are needed due to the increased metabolism in younger patients. Nonetheless, even if not indicated, lithium is often used effectively in children with BD under the age of 12 [78] .
Use in Elderly Patients
Clinical experience has demonstrated that in elderly patients (aged [65 years) lower doses of lithium are sufficient to obtain an efficacy comparable to that in younger patients. Whenever possible, serum levels higher than 0.6 mmol/L should be avoided, and in this patient group doses of 8-12 mmol lithium carbonate (300-450 mg/day) or 6-9 mmol lithium sulfate (330-485 mg/day) can be employed. In elderly patients, the presence of somatic disease and physiological decline of renal function can lead to reduced renal clearance of lithium, with the possibility to achieve toxic levels in serum. Frequent monitoring of both renal function and serum levels of lithium is therefore recommended [79] .
Limitations in the Use of Lithium
Adverse Events
Lithium is an agent with a low therapeutic index (ratio of median toxic to therapeutically effective doses, of approximately 3), and as such requires careful monitoring for adverse effects, both in acute and long-term treatment. A meta-analysis of 385 trials with lithium treatment found that it is associated with reduced urinary concentrating ability, hypothyroidism, weight gain, hyperparathyroidism, and consequent hypercalcemia [80, 81] . Other adverse effects of lithium include tremor, nausea, anorexia, diarrhea, and epigastric discomfort [82] .
The increase in thirst with consequent polydipsia is related to excessive diuresis (polyuria). This side effect usually occurs early, but in contrast to nausea, can continue over time and in some cases, worsen. The polyuria effect of lithium is a troublesome but benign event reported at percentages ranging from 15 to 90% in those undergoing longterm therapy and is due to inhibition of adenyl cyclase in the renal tubules that are sensitive to antidiuretic hormone, leading to a nephrogenic syndrome similar to diabetes insipidus [83] . These effects of lithium are reversible and if the dose of lithium is reduced or interrupted in the early phase of treatment tends to disappear. Weight gain is seen in 25-50% of patients and the effect is one of the most common reasons for lack of adherence or discontinuation of therapy with lithium. Lithium-induced tremors are generally postural and intentional, similar to essential tremors, and can present at any stage of treatment. Tremors are usually symmetrical and worsen upon activities that require motor control (writing, pouring liquids, bringing a glass or cutlery to the mouth). Tremors can be present in the presence of non-toxic levels of lithium in about 25% of patients [84] and tend to worsen during intoxication with lithium, but also in associated with anxiety, stimulants (including caffeine), interaction with other drugs, and abstinence from alcohol.
Nausea is an early side effect and tends to decrease significantly after the first few weeks of treatment. Vomiting is a very rare side effect during treatment with lithium and generally occurs when toxic levels are reached [85] .
Cognitive deficits are not a frequently observed side effect during therapy with lithium. In a meta-analysis, a small but significant deficit in verbal learning, concentration, and memory was found [86] . The dermatological effects of lithium include exacerbation of psoriasis, acne, and hair loss [87] . Treatment in such cases is symptomatic, although other contributing factors should also be investigated.
Thyroid function can be reduced in about 20% of patients (from 3 to 40%) with rates that vary widely depending on the definition of hypothyroidism adopted and the population studied (especially number of years on lithium treatment). A euthyroid goiter is present in 30-55% of patients [88] .
Many serious adverse effects can be avoided by careful prescribing and monitoring; however, clinicians should be aware that chronic toxicity, particularly after longer durations of treatment, can develop even at therapeutic levels [89] [90] [91] .
After adjusting for age, sex, and diabetes, the presence of lithium in serum was associated with an increased risk of stage three (out of five) chronic kidney disease (HR = 1.93, 95% CI 1.76-2.12; p \ 0.0001). Moreover, women younger than 60 years and people with lithium concentrations higher than median were at greatest risk [92] . Renal adverse effects, and in particular renal impairment with lithium, have become of increasing interest, as it is now well established that chronic and endstage renal disease (ESRD) are possible, albeit uncommon, outcomes of long-term lithium therapy [93, 94] . A retrospective cohort study including 6360 patients reported that use of lithium was associated with a hazard ratio for renal failure of 2.5 (95% CI 1.6-4.0) and that the absolute risk was age dependent, with patients of 50 years or older at particular risk of renal failure [95] . However, these findings highlight that the absolute risk of renal failure associated with lithium use remains small.
Kirkham et al [96] studied changes in estimated glomerular filtration rate (eGFR) in patients stratified for different levels of serum lithium [96] . Compared to the reference group (mean eGFR 70.7 mL/min/1.73 m 2 ), groups with lithium levels [1.01 mmol/L showed a significant decrease in eGFR in the first 3 months after exposure. At 6 months (±3 months), the group with lithium levels 1.21-2.0 mmol/L still showed a decline in eGFR, that was, however, not significant. Indeed, the risk of renal dysfunction associated with longer exposure to lithium as well as with advancing age with or without lithium appears to have changed little over the past 10-30 years [97] . Lastly, while some pathological renal changes including the presence of macrocysts, microcysts, glomerulosclerosis, proximal tubular atrophy, and chronic interstitial fibrosis have been reported in patients with longlasting exposure to lithium, ultrasound changes indicative of lithium nephropathy are rare, and are generally only found in patients treated with lithium for [20 years [98] . All the above studies nonetheless emphasize that lithium treatment requires continuous monitoring of renal function, in particular when antihypertensive drugs, as for diuretics and renin-aldosterone system inhibitors, are utilized. Usually, a low dose, a stable blood level, and a single daily dose of lithium are associated with a lower risk of adverse events during long-term treatment [99, 100] .
Compliance to Therapy
As with any medication, compliance to treatment may be a major issue for some patients. Poor adherence to therapy has been reported by a number of studies in BD patients. One study, for example, reported that 32% of BD-I patients were not adherent to therapy, especially those with comorbid personality and substance use disorders [101] . Of note, subjective feelings of cognitive impairment, weight gain, and tremors are the main reasons for treatment suspension or nonadherence, while polyuria and polydipsia are, in fact, much more frequent adverse events but usually they do not lead patients to suspend the treatment [102] . In the Lithium Moderate Dose Use Study (LiTMUS) study, adjunctive moderate dose lithium therapy was compared with optimized treatment in adult outpatients with BD-I or BD-II: 4.50% of participants reported missing at least 30% of their medications in the previous week [103] . Moreover, poor adherence was associated with more manic symptoms and side effects as well as lower lithium serum levels at mid-and post-treatment. Thus, it is clear that while adherence to lithium is generally good, it could be further optimized.
Drug Monitoring
Compared to atypical antipsychotics, lithium has a relatively slower onset of action (6-10 days vs. 2-6 days for risperidone and olanzapine) [104] [105] [106] . At least in the acute setting, the need to achieve adequate plasma levels can discourage its use [107] . Furthermore, while serum lithium levels up to 1 mmol/L are recommended in the treatment of acute mania, levels [0.8 mmol/L may be associated with a greater risk of adverse effects [89] . However, lithium was the first psychiatric treatment with clinically useful drug monitoring by serum assays, well before anticonvulsants and antipsychotics [108] . This allows for effective and safe clinical applications, in view of its narrow therapeutic index or margin of safety [109] . In fact, routine monitoring can help individuals to achieve therapeutic targets (i.e. 0.4-0.8 mmol/L for depression, 0.6-0.8 mmol/L for maintenance, 0.8-1.0 mmol/L for mania) [89, 110] and improve the clinical effectiveness of lithium therapy [85] .
Advantages of Prolonged-Release Formulation
Lithium is available in standard formulations as carbonate, sulfate and citrate salts and in a prolonged-release (PR) form only for the carbonate and sulfate. The PR formulation of lithium has several advantages including consistent serum lithium concentrations, fewer adverse events, and improved adherence to therapy. In particular, lithium PR was associated with a lower incidence of adverse events than lithium immediate-release (9.1 vs. 18.3%) in an observational study in which 47 patients already receiving lithium were switched to once-daily administration of lithium PR [111] . Moreover, after 1 month all patients reported that they preferred lithium PR due to its better tolerability and ease of administration. A single daily administration has been advocated as an alternative to multiple daily administrations, as it may also improve adherence to therapy [112] due to lithium-related adverse events [113] . In this regard, the slower rate of increase in serum concentrations with PR formulations may reduce adverse events such as tremor, upper gastrointestinal cramping, nausea, rash, cognitive dulling, urinary frequency and neuromuscular slowing, although there may be an increase in lower gastrointestinal disturbances, such as diarrhea [113] . Although direct comparative studies between PR and immediate-release formulations of lithium are somewhat limited, the PR formulation of lithium nonetheless appears to have potential advantages over an immediate-release formulation and can be effectively used in the management of BD with fewer adverse events [114] .
Comparative Effectiveness of Lithium
versus Other Treatments for BD in a LongTerm Perspective
Antidepressants
The role of antidepressants in the treatment of BD is still highly debated. While their use along with mood stabilizers may be useful in the short term for treating bipolar depression, their utility in the long term is highly controversial [115] . Antidepressants as maintenance treatment of bipolar disorders have not been widely studied and official guidelines and important consensus papers do not provide conclusive indications. In fact, Pacchiarotti et al [32] , in The International Society for Bipolar Disorders task force report, concluded that ''Evidence for the long-term prophylactic value of antidepressant treatment for patients with bipolar I or II disorder remains poorly studied'' [32] . Furthermore, the British Association for Psychopharmacology stated that it is unclear whether antidepressants should be used in long-term treatment of BD [116] . Moreover, the most recent World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders accepted some usefulness for antidepressants in long-term therapy when combined with antimanic or antipsychotic agents [117] , implicitly assuming the lack of strong evidence of effectiveness.
On the other hand, the few studies showing the efficacy of antidepressants in maintenance treatment, demonstrate that they are less or equal to that of lithium [118] . Hence, it has been suggested that: ''The lack of efficacy with TCAs bodes ill for SRIs and other novel antidepressants, which have never been proven more effective than TCAs in any mood disorder. We conclude that tricyclic antidepressants appear to have relatively low efficacy in the prevention of depression in bipolar disorder, and further one cannot assume that SRIs have any better efficacy'' [119] .
Nevertheless, what is clear is that the inconclusiveness of the evidence for long-term antidepressant use in BD and the reported superiority of the effect of lithium have not affected prescription practices to any substantial degree. A recent large study found that almost 40% of patients, treated in both academic and non-academic centers in Spain, were on long-term pharmacological regimens including at least one antidepressant [120] . This occurred despite important clinical evidence discouraging the longterm use of antidepressants in patients with BD [9] .
The use of antidepressants may increase the risk of switch to the opposite pole and mixed states, promoting cycle acceleration and chronicity. Koukopoulos et al [121] were among the first clinicians to observe that the antidepressants in patients with hyperthymic or cyclothymic temperamental dispositions may trigger hypomania or mania. The episode of elevated mood almost invariably will be followed by another depression until the development of rapid and/or continuous cyclicity. According to the primacy of mania hypothesis, which recently found clinical and neurobiological support, excitatory processes might start the manic-depressive cycle, at least in a relevant minority of cases [122] [123] [124] .
The association between mood switches, cycle acceleration, and antidepressant use has been confirmed by other investigators [125] and rapid cyclic pattern, once established, is associated with treatment resistance and tends to remain stable over years [126] . In patients with a rapidcycling course, the discontinuation of antidepressant drugs seems to improve the response to lithium [125] . Other studies confirmed that the discontinuation of antidepressants should be considered an essential pharmacological indication for treating bipolar patients with a highly recurrent course [123, 127] .
Antidepressants may be also involved in the onset of mixed depressive states that sometimes appear as chronic irritability and dysphoria [128] . They are frequent (almost one-third of all depressions), more severe, more suicidal, and less likely to respond to drug treatment [129] than nonmixed depressions.
Finally, recent reports of increased risk for suicidal ideas and acts associated with antidepressant use have caused considerable alarm among lay public and medical professionals. The question is still debated. In October 2003, the US Food and Drug Administration (FDA) has recommended caution in the use of SSRIs in young people, as a result of a documented increase in planning and attempting suicide. In December 2003, the British Committee on Safety of Medicines (CSM) has banned the use of SSRIs in adolescents, with the exception of fluoxetine. Reanalysis of randomized controlled data [130] , as well as pharmacoepidemiological and large observational studies, do not provide evidence that antidepressants may induce suicidality [131] . However, it is possible to hypothesize that, at least in a subgroup of patients, antidepressants may increase the risk of suicidality by increasing excitatory symptoms in the context of a depressive episode. It is known that mixed depression increases risk of suicide [132] .
Antipsychotics
In the acute manic phase, overall, first-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) drugs are considered to be significantly more rapidly effective than lithium and other mood stabilizers [133, 134] . Combination treatment with SGA agent and a mood stabilizer has a higher response rate in manic episodes than monotherapy with either drug alone [13] . Quetiapine and olanzapine-fluoxetine combination are also recommended in the treatment of acute bipolar depression. Among SGAs, aripiprazole, clozapine, olanzapine, paliperidone, risperidone, and ziprasidone have all been recommended for maintenance therapy, and quetiapine has been considered as highly recommended [10] .
Comparing lithium or quetiapine, the bipolar CHOICE trial found no significant differences between the two drugs considering outcomes at 6 months [135] . Moreover, recent reviews of the available trials reported that combination therapy with quetiapine and lithium was generally more effective than either agent alone in maintenance treatment [136, 137] .
On the basis of this evidence, UK guidelines indicate lithium or quetiapine as first-line treatments for maintenance therapy in patients with predominant manic course of the illness and quetiapine for patients with predominant depressive course [9] , while other guidelines have provided less precise recommendations. Long-term combination therapy with lithium, valproate, or an antipsychotic is recommended for non-responders to monotherapy with predominantly manic course, while quetiapine or lamotrigine may be added to long-term treatment when depressive episodes predominate [9] .
The above considerations on the use of SGAs as mood stabilizers warrant further discussion in a broader context. In the last 30 years, all new antipsychotic drugs introduced onto the market (SGAs opposed to FGAs) have claimed to be ''atypical''. The notion of 'atypicality' has moved through several phases of pseudo-explanation from mesolimbic selectivity, to 5-HT2A mechanisms, and then fast dissociation theory. However, the evidence supporting a common mechanism for atypicality remains very weak and SGAs are not, either structurally or pharmacologically, a homogenous group of drugs and cannot be considered as a ''class''. As a consequence, the idea that SGAs are mood stabilizers, as a class, is not supported by appropriate empirical support.
Moreover, doubts about the superiority in cost-benefit ratio of SGA over FGA clearly emerged from effectiveness trials [138, 139] . Comparisons of SGAs and FGAs have provided confirmation that there is no clear difference in effectiveness between these classes in psychotic patients [140] . No important differences have been observed between any of the antipsychotics in terms of clinical-or cost-effectiveness (except for clozapine in treatment-resistant schizophrenia); the side effects varied from drug to drug and were not determined by the class; and all antipsychotics were associated with potentially serious long-term dose-related and other side effects. Although some of the newer drugs are associated with lower rates of extrapyramidal symptoms/tardive dyskinesia, they are also linked to different and equally severe side effects such as metabolic syndrome and diabetes, and some other newer drugs may have rates of extrapyramidal symptoms/tardive dyskinesia that are similar to the older drugs [141] . We have to take into account that neurologic and metabolic toxicity are particularly important in bipolar patients who are often treated with multiple FGAs and SGAs [142] and are more susceptible to these problems than other medical and psychiatric populations [141] .
RCTs on maintenance treatments of bipolar patients are available for olanzapine [143] , quetiapine [144] , aripiprazole [145] , ziprasidone [146] , and asenapine [147] . All these RCTs selected patients who responded to acute treatment with the study drug (enriched design). The treatment effect evaluated in the long-term phase of an enriched design RCTs can be observed only in patients who have responded to acute-phase therapy with the drug under investigation. Generalization of the results of these studies to other clinical populations should therefore be carried out cautiously, because these treatment benefits are likely to be much less in unselected patients. In other terms, if you give a patient an antipsychotic for acute mania, stop it four weeks later, and then the patient becomes manic again, he probably just relapsed back into the same manic episode and the study is not really focused in long-term prevention, but in relapse of episodes after withdrawal. Clinically, it is worth distinguishing between acute treatment continuation design and recurrence prevention designs.
Another major problem of these studies is the duration of the maintenance phase. An adequate duration is of crucial importance to determine the efficacy and safety of relapse prevention treatments. In all these studies, followups ranged between 6 and 24 months [148] , a short period for a true maintenance study in a disorder where treatment is typically continued for many years. Longer studies are necessary for more accurate assessment of the impact of the relapse prevention treatment on the disease course.
Anticonvulsants
In the last three decades, anticonvulsants have become an integral part of the pharmacological treatment of many psychiatric conditions, first of all BD. The most commonly utilized anticonvulsants in the treatment of BD are carbamazepine and valproic acid, which have shown acute antimanic efficacy and, at least in some patients, a probable long-term mood-stabilizing action, including cases that are refractory or intolerant to lithium [149] .
More recently, the availability of new anticonvulsant compounds with different profiles of efficacy and tolerability has enlarged the therapeutic choices for treatment of BD. Among the new drugs, lamotrigine has been most widely studied, and preliminary evidence also exists for oxcarbazepine in the acute treatment of mania [150] and for gabapentin as a possible option for comorbid anxiety and alcohol or sedative misuse [151] . For oxcarbazepine and gabapentin, however, the data are very preliminary and there are no studies on long-term maintenance treatment of BD.
A number of comparisons have suggested that lithium, valproate, and carbamazepine are equally efficacious against acute mania. On the other hand, there are very few double-blind RCTs in acute mania that report differences in efficacy among active drugs. Lithium was reported to be superior to carbamazepine and somewhat more suitable for specific but difficult to define populations [152] . Two open studies on mixed populations [153, 154] showed the superiority of lithium over carbamazepine for treatment of classic mania, but patients unresponsive to lithium could have a favorable response to carbamazepine [155] . Lithium was also reported to be superior to valproate 1500-3000 mg daily at serum levels of 1.5 mmol/L. In this study, however, a more favorable response to valproate than lithium was associated with high pre-treatment depression scores, thus implying that treatment with valproate may be particularly efficacious in presence of mixed features [156] .
Data on the efficacy of anticonvulsants in bipolar depression are scarce. There are only two small positive studies and a meta-analysis [157] [158] [159] , suggesting that valproate is efficacious in reducing the symptoms of depression and anxiety in BD-I patients, even if recent evidence discourages and limits its use during pregnancy and in fertile women [160] . For carbamazepine, there is only one old, positive, small study [161] . For lamotrigine, five trials on acute BD-I and BD-II depression treatment were negative for the measures of depression identified as primary outcome, showing some minor benefit only on the basis of secondary outcome measures [162] .
Concerning long-term prevention, several studies have suggested that lithium is not superior to carbamazepine, although there is a trend for lithium to perform slightly but not significantly better [153, 163, 164] . Lithium was as efficacious as valproate in the prophylaxis of rapid-cycling patients [165] . Probably the best study comparing lithium, valproate and the lithium-valproate combination is BAL-ANCE [166] . This was not a relapse prevention study (as usually is the case for the study of SGA), but a genuine prophylaxis study. In fact, there was no requirement for a recent acute episode of mania or depression and patients did not have to respond to lithium or valproate to enter the study, but they did have to tolerate those drugs for few weeks, after which they entered the maintenance phase. The study concluded that ''both combination therapy with lithium plus valproate and lithium monotherapy are more likely to prevent relapse than is valproate monotherapy. This benefit seems to be irrespective of baseline severity of illness and is maintained for up to 2 years''. The study could neither reliably confirm nor refute a benefit of combination therapy compared with lithium monotherapy.
Two placebo-controlled RCTs comparing lithium and lamotrigine [167, 168] have suggested that lithium is superior to lamotrigine and placebo at prolonging the time to a manic, hypomanic, or mixed episode and that lamotrigine was superior to placebo at prolonging time to a depressive episode. It is notable that both studies included patients who were stabilized on lamotrigine for 4 weeks, and in both studies, lamotrigine was the central open-label phase treatment either as monotherapy or as adjunctive therapy.
Limitations
Although this conceptual review reports on an update of lithium treatment in both acute phases and long-term effects of lithium, it has its limitations in the lack of systematization of observations. However, we attempted to avoid any bias in the presentation of the results about the efficacy, effectiveness, and side effects of lithium. Our review maybe perceived as leaning too much towards the use of lithium compared to long-term alternatives, but we strongly believe that this medicine is underused and is in need of a renewed interest in the entire interest of the patients.
Conclusions
The chronic nature of BD requires long-term therapy to reduce the risk of relapse and minimize subthreshold symptoms and complications. Lithium has a broad evidence that confirms its efficacy in long-term treatment of BD and is generally recommended as a first-line treatment for long-term therapy in both monotherapy and combination with antipsychotics. In addition to reducing the risk of recurrence, lithium also has other well-recognized advantages that include prevention of suicidal behavior and a neuroprotective effect that warrants further study. It should be further kept in mind that discontinuing lithium in patients with BD is not recommended if successful longterm monotherapy had been achieved. Notwithstanding, as with any long-term therapy, adverse effects are of concern. Regarding lithium, perhaps the most worrisome and beststudied adverse effects are those involving kidney function. However, the risk of clinical renal failure after even decades of therapy can be considered small, which is confirmed also by the relative rarity of pathological macroscopic renal changes even after more than two decades of treatment. Drug monitoring is wholly recommended when using lithium, especially in light of its narrow therapeutic index. Compliance is always an issue for many patients, and a prolonged-release formulation may improve it and at the same time, decrease, the risk of adverse effects.
Regarding other long-term treatments for BD, antidepressants should be used with caution and only in specific clinical situations because of the risk of (hypo)manic switch and cycle acceleration. While antipsychotics-either FGAs or SGAs-may have a role in acute treatment of mania and in prevention of recurrences, the evidence base for their application is likely to be relatively weak when analyzed under scrutiny. Antipsychotics are also associated with a range of adverse events that may not necessarily be class-specific, but which include extrapyramidal symptoms and metabolic effects that may lead to diabetes and cardiovascular events in the long term. Thus, the use of antipsychotics also requires the clinician to individualize treatment based on individual risk profiles and clinical needs. Lastly, anticonvulsants may be considered an important part of long-term management of BD and an important alternative to lithium due to their proven antimanic and mood-stabilizing action.
Lithium must be considered the first-line treatment for the long-term treatment of BD. The available evidence strongly indicates that BD patients should be treated primarily with this agent, sometimes in combination with anticonvulsants, in cases of lithium intolerance or inefficacy, or antidepressants, in the onset of severe depressive states. In few cases lithium can be combined with antipsychotics, only as an adjunct in patients for which these drugs are really indicated (i.e. psychosis, severe agitation). Lithium is not merely a treatment for the episodes, like antipsychotics for mania or antidepressants for depression, but its benefits go beyond the mood symptoms and the combination with antidepressants and/or antipsychotics should be utilized for the shortest possible period of time for episodes of breakthrough depression or mania.
There should be very good reasons not to give lithium to BD patients as initial treatment. Patient preference, by itself, and the necessity of monitoring blood levels and regularly assessing thyroid and kidney function, however, are not sufficient reasons to avoid lithium. Patients should be educated about the many benefits of long-term lithium treatment, besides prophylaxis for mood episodes, including mortality reduction, both by suicide and by cardiovascular death, and neuroprotective effects, with a probable reduction of the risk of dementia and potential protection against cognitive impairment, that is a long-term consequence of multiple mood episodes [66, 169] . Although exaggerated, the limitations of lithium are well known. Long-term chronic renal insufficiency, according to the best prospective studies, is about 1 patient out of 20 [95] ; other renal effects, such as decreased urinary concentration capacity, are more common; hypothyroidism is common but treatable and reversible; other side effects are less frequent than many believe. Weight gain and related metabolic problems are less severe than with valproate and much less severe than with all the SGAs. In some patients, cognitive side effects may be problematic, but in most cases, are not present and can be counteracted by long-term cognitive benefits. Finally, toxicity in overdose may be a major risk, although lithium is the only drug that is demonstrated to prevent suicide with a nine-fold decreased risk [51] .
Although some BD patients cannot take lithium, it should be presented to all. Most should try it and a minority can then stop it if it is not tolerated. With this approach, in our experience many patients can be treated with it and respond satisfactorily, and about one-third do not need association with antidepressants or antipsychotics, which may worsen the course of the illness and produce severe long-term side effects.
